By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the second day of bidding on Tuesday, as investors bet on its growth prospects as ...

Anthem Biosciences IPO sees 20% GMP premium and strong subscriptions on Day 2; check allotment, listing, and key dates now!

Anthem Biosciences' IPO fully subscribed, investors optimistic about growth prospects amid global pharma shift from China to ...

The initial public offering (IPO) of Anthem Biosciences was fully subscribed by the second day of bidding on Tuesday.The IPO ...

Anthem Biosciences IPO got fully subscribed at 1.15 times on the second day of share sale on July 15. The initial share sale ...

The grey market premium for Anthem Biosciences IPO rose from Rs 116 on Monday to Rs 123, as of 10:32 a.m., according to ...

Among investor categories, Non-Institutional Investors (NIIs) have shown the highest interest, bidding 1.55 times their ...

The mainline issue will close for public subscription on Wednesday, July 16. The basis of allotment of shares is likely to be ...

Anthem Biosciences is selling its shares in the price band of Rs 540-570, applied for a minimum of 26 shares and its multiples to raise a total of Rs 3,395 crore between July 14-16.

Anthem Biosciences’ ₹3,395-crore IPO was fully subscribed on Day 2, receiving strong investor demand with bids exceeding the ...

Anthem Biosciences raised ₹1,016.02 crore from 60 institutional investors ahead of its IPO launch on July 14. The offering, ...

Indian drugmaker Anthem Biosciences' ANTH.NS $395 million public listing was fully subscribed on the second day of bidding, as investors bet on the company's growth prospects at a time when global big ...